Today's Top Performers In Health Care

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 27 points (-0.2%) at 16,879 as of Thursday, June 19, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,678 issues advancing vs. 1,278 declining with 191 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. Top gainers within the sector include Medtronic ( MDT), up 1.5%, WellPoint ( WLP), up 1.2%, UnitedHealth Group ( UNH), up 1.1%, Humana ( HUM), up 1.1% and Sanofi ( SNY), up 1.1%. On the negative front, top decliners within the sector include Regeneron Pharmaceuticals ( REGN), down 2.0%, Shire ( SHPG), down 1.8%, Vertex Pharmaceuticals ( VRTX), down 1.4%, Valeant Pharmaceuticals International ( VRX), down 1.1% and Actavis ( ACT), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Smith & Nephew ( SNN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Smith & Nephew is up $1.11 (1.2%) to $91.42 on average volume. Thus far, 113,765 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 226,500 shares. The stock has ranged in price between $90.63-$91.44 after having opened the day at $90.65 as compared to the previous trading day's close of $90.31.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $16.3 billion and is part of the health services industry. Shares are up 25.9% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts who rate Smith & Nephew a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Smith & Nephew Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Celgene ( CELG) is up $5.48 (3.4%) to $166.56 on average volume. Thus far, 2.0 million shares of Celgene exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $163.21-$166.94 after having opened the day at $163.21 as compared to the previous trading day's close of $161.07.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $64.0 billion and is part of the drugs industry. Shares are down 5.4% year-to-date as of the close of trading on Wednesday. Currently there are 19 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, robust revenue growth, notable return on equity, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.62 (0.6%) to $103.43 on light volume. Thus far, 1.8 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.2 million shares. The stock has ranged in price between $102.81-$103.50 after having opened the day at $102.93 as compared to the previous trading day's close of $102.81.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $288.4 billion and is part of the drugs industry. Shares are up 12.2% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Cramer: Don't Fear the Activist

Cramer: Don't Fear the Activist

European Stocks Rise but London Blue Chips Slip on Stronger Pound

European Stocks Rise but London Blue Chips Slip on Stronger Pound

Take Advantage of U.K. Budget to Bag Some Bargains

Take Advantage of U.K. Budget to Bag Some Bargains